Stocktoria
Aligos Therapeutics, Inc. ALGS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-10-16
Aligos Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -4024.9% | -2469.0% | -1423.5% | — | — |
| Net margin | -1106.7% | -3633.6% | -1416.2% | — | — |
| FCF margin | — | -2239.6% | -1276.3% | — | — |
| Return on assets | -27.3% | -187.2% | -57.9% | -65.5% | -54.5% |
| Return on equity | -45.2% | 452.9% | -95.2% | -92.4% | -69.5% |
| Current ratio | 3.90 | 2.86 | 5.90 | 4.03 | 5.25 |
| Revenue growth | -39.5% | -41.7% | — | — | — |
Source: SEC EDGAR filings · CIK 0001799448 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.